Literature DB >> 11264363

CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

S Nikiforow1, K Bottomly, G Miller.   

Abstract

In immunodeficient hosts, Epstein-Barr virus (EBV) often induces extensive B-cell lymphoproliferative disease and lymphoma. Without effective in vitro immune surveillance, B cells infected by the virus readily form immortalized cell lines. In the regression assay, memory T cells inhibit the formation of foci of EBV-transformed B cells that follows recent in vitro infection by EBV. No one has yet addressed which T cell regulates the early proliferative phase of B cells newly infected by EBV. Using new quantitative methods, we analyzed T-cell surveillance of EBV-mediated B-cell proliferation. We found that CD4+ T cells play a significant role in limiting proliferation of newly infected, activated CD23+ B cells. In the absence of T cells, EBV-infected CD23+ B cells divided rapidly during the first 3 weeks after infection. Removal of CD4+ but not CD8+ T cells also abrogated immune control. Purified CD4+ T cells eliminated outgrowth when added to EBV-infected B cells. Thus, unlike the killing of EBV-infected lymphoblastoid cell lines, in which CD8+ cytolytic T cells play an essential role, prevention of early-phase EBV-induced B-cell proliferation requires CD4+ effector T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264363      PMCID: PMC114865          DOI: 10.1128/JVI.75.8.3740-3752.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Long-term C-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures.

Authors:  A B Rickinson; D J Moss; J H Pope
Journal:  Int J Cancer       Date:  1979-05-15       Impact factor: 7.396

2.  Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein-Barr virus-associated antigens.

Authors:  B M Reedman; J Hilgers; F Hilgers; G Klein
Journal:  Int J Cancer       Date:  1975-04-15       Impact factor: 7.396

3.  Assay for Epstein-Barr virus based on stimulation of DNA synthesis in mixed leukocytes from human umbilical cord blood.

Authors:  J Robinson
Journal:  J Virol       Date:  1975-05       Impact factor: 5.103

4.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

5.  Epstein-Barr viral nuclear antigen (EBNA) in tumor cell imprints of experimental lymphoma of marmosets.

Authors:  G Miller; D Coope
Journal:  Trans Assoc Am Physicians       Date:  1974

Review 6.  A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells.

Authors:  D A Thorley-Lawson; G J Babcock
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

7.  Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.

Authors:  S Honda; T Takasaki; K Okuno; M Yasutomi; I Kurane
Journal:  Acta Virol       Date:  1998-11       Impact factor: 1.162

8.  CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.

Authors:  Q Sun; R L Burton; K E Pollok; D J Emanuel; K G Lucas
Journal:  Cell Immunol       Date:  1999-08-01       Impact factor: 4.868

9.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  IARC Sci Publ       Date:  1975

10.  Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.

Authors:  G J Babcock; L L Decker; R B Freeman; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

View more
  28 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Cutting edge: activation of virus-specific CD4 T cells throughout γ-herpesvirus latency.

Authors:  Michael L Freeman; Claire E Burkum; Kathleen G Lanzer; Meghan K Jensen; Mushtaq Ahmed; Eric J Yager; Emilio Flaño; Gary M Winslow; David L Woodland; Marcia A Blackman
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

Review 3.  Adoptive T-Cell Immunotherapy.

Authors:  Stephen Gottschalk; Cliona M Rooney
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Authors:  Timothy E Quan; Robert M Roman; Benjamin J Rudenga; V Michael Holers; Joseph E Craft
Journal:  Arthritis Rheum       Date:  2010-06

5.  Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.

Authors:  Nancy H Gudgeon; Graham S Taylor; Heather M Long; Tracey A Haigh; Alan B Rickinson
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL.

Authors:  Allison M Beal; Nadia Anikeeva; Rajat Varma; Thomas O Cameron; Philip J Norris; Michael L Dustin; Yuri Sykulev
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

7.  Persistent gamma-herpesvirus infection induces a CD4 T cell response containing functionally distinct effector populations.

Authors:  Kathleen A Stuller; Stephanie S Cush; Emilio Flaño
Journal:  J Immunol       Date:  2010-03-05       Impact factor: 5.422

Review 8.  Immunotherapy against cancer-related viruses.

Authors:  Haruko Tashiro; Malcolm K Brenner
Journal:  Cell Res       Date:  2016-12-23       Impact factor: 25.617

9.  Efficient Culture of Human Naive and Memory B Cells for Use as APCs.

Authors:  Kuei-Ying Su; Akiko Watanabe; Chen-Hao Yeh; Garnett Kelsoe; Masayuki Kuraoka
Journal:  J Immunol       Date:  2016-10-10       Impact factor: 5.422

10.  Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines.

Authors:  Sumita Bhaduri-McIntosh; Marisa J Rotenberg; Benjamin Gardner; Marie Robert; George Miller
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.